To assess the effects of 90 days of oral Pep19 on regional fat distribution, metabolic measures, and safety in adults with obesity.
Approach:
Design and participants: Randomized, double-blind, placebo-controlled trial of 60 adults aged 21–60 years with obesity; 56 completed the study.
Intervention and outcomes: Participants received Pep19 5 mg, Pep19 10 mg, or placebo once daily. The primary endpoint was change in the DXA-measured android-to-gynoid fat ratio at day 90.
Key Findings:
Pep19 10 mg reduced the android-to-gynoid fat ratio versus placebo by an adjusted 3.58 percentage points; the 5-mg dose did not significantly affect the primary endpoint.
The 10-mg dose was associated with reduced abdominal and total skinfold thickness, but body weight, BMI, total fat mass, and lean mass did not differ significantly between groups.
HbA1c and HOMA-IR improved in Pep19 groups, while fasting glucose remained unchanged. These were secondary outcomes.
Lipid profiles, inflammatory biomarkers, and blood pressure showed no significant between-group differences.
No treatment-related toxicologic signals or clinically relevant laboratory abnormalities were identified during the 90-day study.
Interpretation:
The authors stated that the findings support improved metabolic regulation, but do not provide definitive proof of improved insulin sensitivity.
Limitations:
The sample was modest and follow-up was limited to 90 days.
The primary endpoint was significant as a percentage of baseline, but not in the supporting absolute-scale analysis.
HbA1c and HOMA-IR findings were secondary; baseline insulin resistance was higher in the 10-mg group.
Diet and physical activity were not objectively monitored, and target engagement or other mechanistic biomarkers were not assessed.
The exploratory responder analysis and recruitment from one geographic setting limit generalizability.
Conclusion:
Larger, longer-term trials are needed to assess whether the observed changes persist and translate into meaningful cardiometabolic benefits.